RC48-ADC and JS001

DRUG2 trials

Sponsors

Peking University Cancer Hospital & Institute, Jinling Hospital, China

Conditions

CarcinomaUTUCUpper Tract Urothelial CarcinomaUrothelial Carcinoma

Phase 1

A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer

Peking University Cancer Hospital & InstituteUrothelial Carcinoma

Start: 2020-02-15End: 2021-12-31Target: 36Updated: 2020-02-13

Phase 2

A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma

RecruitingNCT05917158

Jinling Hospital, ChinaCarcinoma, Upper Tract Urothelial Carcinoma, UTUC

Start: 2022-11-23End: 2028-12-31Target: 30Updated: 2025-01-22

Related Papers

Efficacy and safety of disitamab vedotin (RC48) combined with toripalimab as adjuvant therapy after radical surgery for patients with HER2-overexpression upper tract urothelial cancer (UTUC): A single-arm, prospective, phase 2 clinical trial.

Journal of Clinical Oncology2025-05-281 citations

Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.

Journal of Clinical Oncology2023-06-0123 citations

Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma.

Journal of Clinical Oncology2022-06-0125 citations

Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma.

Journal of Clinical Oncology2022-02-1641 citations

RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.

Journal of Clinical Oncology2021-05-2013 citations